Long-term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size: a report by the Nagasaki CML Study Group
Imatinib has dramatically improved long-term survival of chronic myelogenous leukemia (CML) patients. To analyze its efficacy in a practical setting, we registered most of CML patients in Nagasaki Prefecture of Japan. Of these, 73 patients received imatinib as an initial therapy. The overall surviva...
Gespeichert in:
| Veröffentlicht in: | International journal of hematology 2009-04, Vol.89 (3), p.319-325 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 325 |
|---|---|
| container_issue | 3 |
| container_start_page | 319 |
| container_title | International journal of hematology |
| container_volume | 89 |
| creator | Sakai, Mari Miyazaki, Yasushi Matsuo, Emi Moriuchi, Yukiyoshi Hata, Tomoko Fukushima, Takuya Imaizumi, Yoshitaka Imanishi, Daisuke Taguchi, Jun Iwanaga, Masako Tsushima, Hideki Inoue, Yoriko Takasaki, Yumi Tsuchiya, Takeshi Komoda, Minori Ando, Koji Horio, Kensuke Moriwaki, Yuji Tominaga, Shinya Itonaga, Hidehiro Nagai, Kazuhiro Tsukasaki, Kunihiro Tsutsumi, Chizuko Sawayama, Yasushi Yamasaki, Reishi Ogawa, Daisuke Kawaguchi, Yasuhisa Ikeda, Shuichi Yoshida, Shinichiro Onimaru, Yasuyuki Tawara, Masayuki Atogami, Sunao Koida, Satoshi Joh, Tatsuro Yamamura, Masaomi Matsuo, Yuji Soda, Hisashi Nonaka, Hiroaki Jinnai, Itsuro Kuriyama, Kazutaka Tomonaga, Masao |
| description | Imatinib has dramatically improved long-term survival of chronic myelogenous leukemia (CML) patients. To analyze its efficacy in a practical setting, we registered most of CML patients in Nagasaki Prefecture of Japan. Of these, 73 patients received imatinib as an initial therapy. The overall survival rate of these patients was 88.7% at 6 years, and the cumulative complete cytogenetic response rate was 82.5% at 18 months. These results are comparable with the data of other reports including the IRIS study; however, the administered imatinib dose was smaller in our study than that in other reports. To address these discrepancies, we measured the trough concentration of imatinib among 35 patients. Although 39% of the patients were administered less than 400 mg/day, the trough level was comparable to those of previous reports. The trough level of imatinib showed a significant relationship with its efficacy, and was clearly related to dose of imatinib administrated and dose of imatinib divided by body surface area (BSA). Considering the smaller BSA of Japanese patients as compared to those of foreign origin, the results suggest that a lower dose of imatinib could maintain enough trough level and provided excellent results for the treatment of CML in our registry. |
| doi_str_mv | 10.1007/s12185-009-0263-z |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67127126</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1891716171</sourcerecordid><originalsourceid>FETCH-LOGICAL-c422t-6268164731dfe476e31338b2751a96ffe51fbb847c591916728df4eedeab08b63</originalsourceid><addsrcrecordid>eNp1kUGr1DAUhYMovvHpD3AjwYW7am7aJq07GfQpjLpQ1yFtbzp5dpKapMjMr_InmjIDA4IQCNzznXNDDiHPgb0GxuSbCByaumCsLRgXZXF6QDbQiLoopawekg1reV3UEtgNeRLjPWMgWSUfkxtouRC8FhvyZ-fdWCQMB4rG2F73R-oNtQedrLMdtY5qOgfdp6xNNGLK85HaSHsfAk464UB_27S_WlLwy7jPuuvRpZCn3tG012l1WWemBbMy0O5IOz8cabQnfJu3BJx9SOs47ZF-0aOO-qel2887-i0tGbzLwfNT8sjoKeKzy31Lfnx4_337sdh9vfu0fbcr-orzVAguGhCVLGEwWEmBJZRl03FZg26FMViD6bqmkn3dQgtC8mYwFeKAumNNJ8pb8uqcOwf_a8GY1MHGHqdJO_RLVEICz2cFX_4D3vsluPw2xUGWsqoqyBCcoT74GAMaNYf8YeGogKm1S3XuUuUu1dqlOmXPi0vw0h1wuDou5WWAn4GYJTdiuG7-f-pfagusdQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>217374441</pqid></control><display><type>article</type><title>Long-term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size: a report by the Nagasaki CML Study Group</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Sakai, Mari ; Miyazaki, Yasushi ; Matsuo, Emi ; Moriuchi, Yukiyoshi ; Hata, Tomoko ; Fukushima, Takuya ; Imaizumi, Yoshitaka ; Imanishi, Daisuke ; Taguchi, Jun ; Iwanaga, Masako ; Tsushima, Hideki ; Inoue, Yoriko ; Takasaki, Yumi ; Tsuchiya, Takeshi ; Komoda, Minori ; Ando, Koji ; Horio, Kensuke ; Moriwaki, Yuji ; Tominaga, Shinya ; Itonaga, Hidehiro ; Nagai, Kazuhiro ; Tsukasaki, Kunihiro ; Tsutsumi, Chizuko ; Sawayama, Yasushi ; Yamasaki, Reishi ; Ogawa, Daisuke ; Kawaguchi, Yasuhisa ; Ikeda, Shuichi ; Yoshida, Shinichiro ; Onimaru, Yasuyuki ; Tawara, Masayuki ; Atogami, Sunao ; Koida, Satoshi ; Joh, Tatsuro ; Yamamura, Masaomi ; Matsuo, Yuji ; Soda, Hisashi ; Nonaka, Hiroaki ; Jinnai, Itsuro ; Kuriyama, Kazutaka ; Tomonaga, Masao</creator><creatorcontrib>Sakai, Mari ; Miyazaki, Yasushi ; Matsuo, Emi ; Moriuchi, Yukiyoshi ; Hata, Tomoko ; Fukushima, Takuya ; Imaizumi, Yoshitaka ; Imanishi, Daisuke ; Taguchi, Jun ; Iwanaga, Masako ; Tsushima, Hideki ; Inoue, Yoriko ; Takasaki, Yumi ; Tsuchiya, Takeshi ; Komoda, Minori ; Ando, Koji ; Horio, Kensuke ; Moriwaki, Yuji ; Tominaga, Shinya ; Itonaga, Hidehiro ; Nagai, Kazuhiro ; Tsukasaki, Kunihiro ; Tsutsumi, Chizuko ; Sawayama, Yasushi ; Yamasaki, Reishi ; Ogawa, Daisuke ; Kawaguchi, Yasuhisa ; Ikeda, Shuichi ; Yoshida, Shinichiro ; Onimaru, Yasuyuki ; Tawara, Masayuki ; Atogami, Sunao ; Koida, Satoshi ; Joh, Tatsuro ; Yamamura, Masaomi ; Matsuo, Yuji ; Soda, Hisashi ; Nonaka, Hiroaki ; Jinnai, Itsuro ; Kuriyama, Kazutaka ; Tomonaga, Masao</creatorcontrib><description>Imatinib has dramatically improved long-term survival of chronic myelogenous leukemia (CML) patients. To analyze its efficacy in a practical setting, we registered most of CML patients in Nagasaki Prefecture of Japan. Of these, 73 patients received imatinib as an initial therapy. The overall survival rate of these patients was 88.7% at 6 years, and the cumulative complete cytogenetic response rate was 82.5% at 18 months. These results are comparable with the data of other reports including the IRIS study; however, the administered imatinib dose was smaller in our study than that in other reports. To address these discrepancies, we measured the trough concentration of imatinib among 35 patients. Although 39% of the patients were administered less than 400 mg/day, the trough level was comparable to those of previous reports. The trough level of imatinib showed a significant relationship with its efficacy, and was clearly related to dose of imatinib administrated and dose of imatinib divided by body surface area (BSA). Considering the smaller BSA of Japanese patients as compared to those of foreign origin, the results suggest that a lower dose of imatinib could maintain enough trough level and provided excellent results for the treatment of CML in our registry.</description><identifier>ISSN: 0925-5710</identifier><identifier>EISSN: 1865-3774</identifier><identifier>DOI: 10.1007/s12185-009-0263-z</identifier><identifier>PMID: 19266256</identifier><language>eng</language><publisher>Tokyo: Springer Japan</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents - therapeutic use ; Benzamides ; Body Size - drug effects ; Female ; Hematology ; Humans ; Imatinib Mesylate ; Japan ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Oncology ; Original Article ; Piperazines - therapeutic use ; Pyrimidines - therapeutic use ; Survival Rate ; Time Factors</subject><ispartof>International journal of hematology, 2009-04, Vol.89 (3), p.319-325</ispartof><rights>The Japanese Society of Hematology 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c422t-6268164731dfe476e31338b2751a96ffe51fbb847c591916728df4eedeab08b63</citedby><cites>FETCH-LOGICAL-c422t-6268164731dfe476e31338b2751a96ffe51fbb847c591916728df4eedeab08b63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12185-009-0263-z$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12185-009-0263-z$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19266256$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sakai, Mari</creatorcontrib><creatorcontrib>Miyazaki, Yasushi</creatorcontrib><creatorcontrib>Matsuo, Emi</creatorcontrib><creatorcontrib>Moriuchi, Yukiyoshi</creatorcontrib><creatorcontrib>Hata, Tomoko</creatorcontrib><creatorcontrib>Fukushima, Takuya</creatorcontrib><creatorcontrib>Imaizumi, Yoshitaka</creatorcontrib><creatorcontrib>Imanishi, Daisuke</creatorcontrib><creatorcontrib>Taguchi, Jun</creatorcontrib><creatorcontrib>Iwanaga, Masako</creatorcontrib><creatorcontrib>Tsushima, Hideki</creatorcontrib><creatorcontrib>Inoue, Yoriko</creatorcontrib><creatorcontrib>Takasaki, Yumi</creatorcontrib><creatorcontrib>Tsuchiya, Takeshi</creatorcontrib><creatorcontrib>Komoda, Minori</creatorcontrib><creatorcontrib>Ando, Koji</creatorcontrib><creatorcontrib>Horio, Kensuke</creatorcontrib><creatorcontrib>Moriwaki, Yuji</creatorcontrib><creatorcontrib>Tominaga, Shinya</creatorcontrib><creatorcontrib>Itonaga, Hidehiro</creatorcontrib><creatorcontrib>Nagai, Kazuhiro</creatorcontrib><creatorcontrib>Tsukasaki, Kunihiro</creatorcontrib><creatorcontrib>Tsutsumi, Chizuko</creatorcontrib><creatorcontrib>Sawayama, Yasushi</creatorcontrib><creatorcontrib>Yamasaki, Reishi</creatorcontrib><creatorcontrib>Ogawa, Daisuke</creatorcontrib><creatorcontrib>Kawaguchi, Yasuhisa</creatorcontrib><creatorcontrib>Ikeda, Shuichi</creatorcontrib><creatorcontrib>Yoshida, Shinichiro</creatorcontrib><creatorcontrib>Onimaru, Yasuyuki</creatorcontrib><creatorcontrib>Tawara, Masayuki</creatorcontrib><creatorcontrib>Atogami, Sunao</creatorcontrib><creatorcontrib>Koida, Satoshi</creatorcontrib><creatorcontrib>Joh, Tatsuro</creatorcontrib><creatorcontrib>Yamamura, Masaomi</creatorcontrib><creatorcontrib>Matsuo, Yuji</creatorcontrib><creatorcontrib>Soda, Hisashi</creatorcontrib><creatorcontrib>Nonaka, Hiroaki</creatorcontrib><creatorcontrib>Jinnai, Itsuro</creatorcontrib><creatorcontrib>Kuriyama, Kazutaka</creatorcontrib><creatorcontrib>Tomonaga, Masao</creatorcontrib><title>Long-term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size: a report by the Nagasaki CML Study Group</title><title>International journal of hematology</title><addtitle>Int J Hematol</addtitle><addtitle>Int J Hematol</addtitle><description>Imatinib has dramatically improved long-term survival of chronic myelogenous leukemia (CML) patients. To analyze its efficacy in a practical setting, we registered most of CML patients in Nagasaki Prefecture of Japan. Of these, 73 patients received imatinib as an initial therapy. The overall survival rate of these patients was 88.7% at 6 years, and the cumulative complete cytogenetic response rate was 82.5% at 18 months. These results are comparable with the data of other reports including the IRIS study; however, the administered imatinib dose was smaller in our study than that in other reports. To address these discrepancies, we measured the trough concentration of imatinib among 35 patients. Although 39% of the patients were administered less than 400 mg/day, the trough level was comparable to those of previous reports. The trough level of imatinib showed a significant relationship with its efficacy, and was clearly related to dose of imatinib administrated and dose of imatinib divided by body surface area (BSA). Considering the smaller BSA of Japanese patients as compared to those of foreign origin, the results suggest that a lower dose of imatinib could maintain enough trough level and provided excellent results for the treatment of CML in our registry.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Benzamides</subject><subject>Body Size - drug effects</subject><subject>Female</subject><subject>Hematology</subject><subject>Humans</subject><subject>Imatinib Mesylate</subject><subject>Japan</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Piperazines - therapeutic use</subject><subject>Pyrimidines - therapeutic use</subject><subject>Survival Rate</subject><subject>Time Factors</subject><issn>0925-5710</issn><issn>1865-3774</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kUGr1DAUhYMovvHpD3AjwYW7am7aJq07GfQpjLpQ1yFtbzp5dpKapMjMr_InmjIDA4IQCNzznXNDDiHPgb0GxuSbCByaumCsLRgXZXF6QDbQiLoopawekg1reV3UEtgNeRLjPWMgWSUfkxtouRC8FhvyZ-fdWCQMB4rG2F73R-oNtQedrLMdtY5qOgfdp6xNNGLK85HaSHsfAk464UB_27S_WlLwy7jPuuvRpZCn3tG012l1WWemBbMy0O5IOz8cabQnfJu3BJx9SOs47ZF-0aOO-qel2887-i0tGbzLwfNT8sjoKeKzy31Lfnx4_337sdh9vfu0fbcr-orzVAguGhCVLGEwWEmBJZRl03FZg26FMViD6bqmkn3dQgtC8mYwFeKAumNNJ8pb8uqcOwf_a8GY1MHGHqdJO_RLVEICz2cFX_4D3vsluPw2xUGWsqoqyBCcoT74GAMaNYf8YeGogKm1S3XuUuUu1dqlOmXPi0vw0h1wuDou5WWAn4GYJTdiuG7-f-pfagusdQ</recordid><startdate>20090401</startdate><enddate>20090401</enddate><creator>Sakai, Mari</creator><creator>Miyazaki, Yasushi</creator><creator>Matsuo, Emi</creator><creator>Moriuchi, Yukiyoshi</creator><creator>Hata, Tomoko</creator><creator>Fukushima, Takuya</creator><creator>Imaizumi, Yoshitaka</creator><creator>Imanishi, Daisuke</creator><creator>Taguchi, Jun</creator><creator>Iwanaga, Masako</creator><creator>Tsushima, Hideki</creator><creator>Inoue, Yoriko</creator><creator>Takasaki, Yumi</creator><creator>Tsuchiya, Takeshi</creator><creator>Komoda, Minori</creator><creator>Ando, Koji</creator><creator>Horio, Kensuke</creator><creator>Moriwaki, Yuji</creator><creator>Tominaga, Shinya</creator><creator>Itonaga, Hidehiro</creator><creator>Nagai, Kazuhiro</creator><creator>Tsukasaki, Kunihiro</creator><creator>Tsutsumi, Chizuko</creator><creator>Sawayama, Yasushi</creator><creator>Yamasaki, Reishi</creator><creator>Ogawa, Daisuke</creator><creator>Kawaguchi, Yasuhisa</creator><creator>Ikeda, Shuichi</creator><creator>Yoshida, Shinichiro</creator><creator>Onimaru, Yasuyuki</creator><creator>Tawara, Masayuki</creator><creator>Atogami, Sunao</creator><creator>Koida, Satoshi</creator><creator>Joh, Tatsuro</creator><creator>Yamamura, Masaomi</creator><creator>Matsuo, Yuji</creator><creator>Soda, Hisashi</creator><creator>Nonaka, Hiroaki</creator><creator>Jinnai, Itsuro</creator><creator>Kuriyama, Kazutaka</creator><creator>Tomonaga, Masao</creator><general>Springer Japan</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20090401</creationdate><title>Long-term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size: a report by the Nagasaki CML Study Group</title><author>Sakai, Mari ; Miyazaki, Yasushi ; Matsuo, Emi ; Moriuchi, Yukiyoshi ; Hata, Tomoko ; Fukushima, Takuya ; Imaizumi, Yoshitaka ; Imanishi, Daisuke ; Taguchi, Jun ; Iwanaga, Masako ; Tsushima, Hideki ; Inoue, Yoriko ; Takasaki, Yumi ; Tsuchiya, Takeshi ; Komoda, Minori ; Ando, Koji ; Horio, Kensuke ; Moriwaki, Yuji ; Tominaga, Shinya ; Itonaga, Hidehiro ; Nagai, Kazuhiro ; Tsukasaki, Kunihiro ; Tsutsumi, Chizuko ; Sawayama, Yasushi ; Yamasaki, Reishi ; Ogawa, Daisuke ; Kawaguchi, Yasuhisa ; Ikeda, Shuichi ; Yoshida, Shinichiro ; Onimaru, Yasuyuki ; Tawara, Masayuki ; Atogami, Sunao ; Koida, Satoshi ; Joh, Tatsuro ; Yamamura, Masaomi ; Matsuo, Yuji ; Soda, Hisashi ; Nonaka, Hiroaki ; Jinnai, Itsuro ; Kuriyama, Kazutaka ; Tomonaga, Masao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c422t-6268164731dfe476e31338b2751a96ffe51fbb847c591916728df4eedeab08b63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Benzamides</topic><topic>Body Size - drug effects</topic><topic>Female</topic><topic>Hematology</topic><topic>Humans</topic><topic>Imatinib Mesylate</topic><topic>Japan</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Piperazines - therapeutic use</topic><topic>Pyrimidines - therapeutic use</topic><topic>Survival Rate</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sakai, Mari</creatorcontrib><creatorcontrib>Miyazaki, Yasushi</creatorcontrib><creatorcontrib>Matsuo, Emi</creatorcontrib><creatorcontrib>Moriuchi, Yukiyoshi</creatorcontrib><creatorcontrib>Hata, Tomoko</creatorcontrib><creatorcontrib>Fukushima, Takuya</creatorcontrib><creatorcontrib>Imaizumi, Yoshitaka</creatorcontrib><creatorcontrib>Imanishi, Daisuke</creatorcontrib><creatorcontrib>Taguchi, Jun</creatorcontrib><creatorcontrib>Iwanaga, Masako</creatorcontrib><creatorcontrib>Tsushima, Hideki</creatorcontrib><creatorcontrib>Inoue, Yoriko</creatorcontrib><creatorcontrib>Takasaki, Yumi</creatorcontrib><creatorcontrib>Tsuchiya, Takeshi</creatorcontrib><creatorcontrib>Komoda, Minori</creatorcontrib><creatorcontrib>Ando, Koji</creatorcontrib><creatorcontrib>Horio, Kensuke</creatorcontrib><creatorcontrib>Moriwaki, Yuji</creatorcontrib><creatorcontrib>Tominaga, Shinya</creatorcontrib><creatorcontrib>Itonaga, Hidehiro</creatorcontrib><creatorcontrib>Nagai, Kazuhiro</creatorcontrib><creatorcontrib>Tsukasaki, Kunihiro</creatorcontrib><creatorcontrib>Tsutsumi, Chizuko</creatorcontrib><creatorcontrib>Sawayama, Yasushi</creatorcontrib><creatorcontrib>Yamasaki, Reishi</creatorcontrib><creatorcontrib>Ogawa, Daisuke</creatorcontrib><creatorcontrib>Kawaguchi, Yasuhisa</creatorcontrib><creatorcontrib>Ikeda, Shuichi</creatorcontrib><creatorcontrib>Yoshida, Shinichiro</creatorcontrib><creatorcontrib>Onimaru, Yasuyuki</creatorcontrib><creatorcontrib>Tawara, Masayuki</creatorcontrib><creatorcontrib>Atogami, Sunao</creatorcontrib><creatorcontrib>Koida, Satoshi</creatorcontrib><creatorcontrib>Joh, Tatsuro</creatorcontrib><creatorcontrib>Yamamura, Masaomi</creatorcontrib><creatorcontrib>Matsuo, Yuji</creatorcontrib><creatorcontrib>Soda, Hisashi</creatorcontrib><creatorcontrib>Nonaka, Hiroaki</creatorcontrib><creatorcontrib>Jinnai, Itsuro</creatorcontrib><creatorcontrib>Kuriyama, Kazutaka</creatorcontrib><creatorcontrib>Tomonaga, Masao</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sakai, Mari</au><au>Miyazaki, Yasushi</au><au>Matsuo, Emi</au><au>Moriuchi, Yukiyoshi</au><au>Hata, Tomoko</au><au>Fukushima, Takuya</au><au>Imaizumi, Yoshitaka</au><au>Imanishi, Daisuke</au><au>Taguchi, Jun</au><au>Iwanaga, Masako</au><au>Tsushima, Hideki</au><au>Inoue, Yoriko</au><au>Takasaki, Yumi</au><au>Tsuchiya, Takeshi</au><au>Komoda, Minori</au><au>Ando, Koji</au><au>Horio, Kensuke</au><au>Moriwaki, Yuji</au><au>Tominaga, Shinya</au><au>Itonaga, Hidehiro</au><au>Nagai, Kazuhiro</au><au>Tsukasaki, Kunihiro</au><au>Tsutsumi, Chizuko</au><au>Sawayama, Yasushi</au><au>Yamasaki, Reishi</au><au>Ogawa, Daisuke</au><au>Kawaguchi, Yasuhisa</au><au>Ikeda, Shuichi</au><au>Yoshida, Shinichiro</au><au>Onimaru, Yasuyuki</au><au>Tawara, Masayuki</au><au>Atogami, Sunao</au><au>Koida, Satoshi</au><au>Joh, Tatsuro</au><au>Yamamura, Masaomi</au><au>Matsuo, Yuji</au><au>Soda, Hisashi</au><au>Nonaka, Hiroaki</au><au>Jinnai, Itsuro</au><au>Kuriyama, Kazutaka</au><au>Tomonaga, Masao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size: a report by the Nagasaki CML Study Group</atitle><jtitle>International journal of hematology</jtitle><stitle>Int J Hematol</stitle><addtitle>Int J Hematol</addtitle><date>2009-04-01</date><risdate>2009</risdate><volume>89</volume><issue>3</issue><spage>319</spage><epage>325</epage><pages>319-325</pages><issn>0925-5710</issn><eissn>1865-3774</eissn><abstract>Imatinib has dramatically improved long-term survival of chronic myelogenous leukemia (CML) patients. To analyze its efficacy in a practical setting, we registered most of CML patients in Nagasaki Prefecture of Japan. Of these, 73 patients received imatinib as an initial therapy. The overall survival rate of these patients was 88.7% at 6 years, and the cumulative complete cytogenetic response rate was 82.5% at 18 months. These results are comparable with the data of other reports including the IRIS study; however, the administered imatinib dose was smaller in our study than that in other reports. To address these discrepancies, we measured the trough concentration of imatinib among 35 patients. Although 39% of the patients were administered less than 400 mg/day, the trough level was comparable to those of previous reports. The trough level of imatinib showed a significant relationship with its efficacy, and was clearly related to dose of imatinib administrated and dose of imatinib divided by body surface area (BSA). Considering the smaller BSA of Japanese patients as compared to those of foreign origin, the results suggest that a lower dose of imatinib could maintain enough trough level and provided excellent results for the treatment of CML in our registry.</abstract><cop>Tokyo</cop><pub>Springer Japan</pub><pmid>19266256</pmid><doi>10.1007/s12185-009-0263-z</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0925-5710 |
| ispartof | International journal of hematology, 2009-04, Vol.89 (3), p.319-325 |
| issn | 0925-5710 1865-3774 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67127126 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adolescent Adult Aged Aged, 80 and over Antineoplastic Agents - therapeutic use Benzamides Body Size - drug effects Female Hematology Humans Imatinib Mesylate Japan Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology Male Medicine Medicine & Public Health Middle Aged Oncology Original Article Piperazines - therapeutic use Pyrimidines - therapeutic use Survival Rate Time Factors |
| title | Long-term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size: a report by the Nagasaki CML Study Group |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T00%3A37%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-term%20efficacy%20of%20imatinib%20in%20a%20practical%20setting%20is%20correlated%20with%20imatinib%20trough%20concentration%20that%20is%20influenced%20by%20body%20size:%20a%20report%20by%20the%20Nagasaki%20CML%20Study%20Group&rft.jtitle=International%20journal%20of%20hematology&rft.au=Sakai,%20Mari&rft.date=2009-04-01&rft.volume=89&rft.issue=3&rft.spage=319&rft.epage=325&rft.pages=319-325&rft.issn=0925-5710&rft.eissn=1865-3774&rft_id=info:doi/10.1007/s12185-009-0263-z&rft_dat=%3Cproquest_cross%3E1891716171%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=217374441&rft_id=info:pmid/19266256&rfr_iscdi=true |